The New England journal of medicine, 2021-04, Vol.384 (17), p.1589-1600
- Chertow, Glenn M
- Pergola, Pablo E
- Farag, Youssef M.K
- Agarwal, Rajiv
- Arnold, Susan
- Bako, Gabriel
- Block, Geoffrey A
- Burke, Steven
- Castillo, Fausto P
- Jardine, Alan G
- Khawaja, Zeeshan
- Koury, Mark J
- Lewis, Eldrin F
- Lin, Tim
- Luo, Wenli
- Maroni, Bradley J
- Matsushita, Kunihiro
- McCullough, Peter A
- Parfrey, Patrick S
- Roy-Chaudhury, Prabir
- Sarnak, Mark J
- Sharma, Amit
- Spinowitz, Bruce
- Tseng, Carol
- Tumlin, James
- Vargo, Dennis L
- Walters, Kimberly A
- Winkelmayer, Wolfgang C
- Wittes, Janet
- Eckardt, Kai-Uwe
2021
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Chertow, Glenn M
- Pergola, Pablo E
- Farag, Youssef M.K
- Agarwal, Rajiv
- Arnold, Susan
- Bako, Gabriel
- Block, Geoffrey A
- Burke, Steven
- Castillo, Fausto P
- Jardine, Alan G
- Khawaja, Zeeshan
- Koury, Mark J
- Lewis, Eldrin F
- Lin, Tim
- Luo, Wenli
- Maroni, Bradley J
- Matsushita, Kunihiro
- McCullough, Peter A
- Parfrey, Patrick S
- Roy-Chaudhury, Prabir
- Sarnak, Mark J
- Sharma, Amit
- Spinowitz, Bruce
- Tseng, Carol
- Tumlin, James
- Vargo, Dennis L
- Walters, Kimberly A
- Winkelmayer, Wolfgang C
- Wittes, Janet
- Eckardt, Kai-Uwe
- Titel
- Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD
- Ist Teil von
- The New England journal of medicine, 2021-04, Vol.384 (17), p.1589-1600
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2021
- Quelle
- EZB-FREE-00999 freely available EZB journals
- Beschreibungen/Notizen
- Two randomized, phase 3, open-label noninferiority trials compared vadadustat with darbepoetin alfa in patients with non–dialysis-dependent chronic kidney disease. Vadadustat, as compared with darbepoetin alfa, met the prespecified noninferiority criterion for hematologic efficacy but not for cardiovascular safety.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2035938Titel-ID: cdi_proquest_miscellaneous_2519812433
- Format
- –
- Schlagworte
- Administration, Oral, Aged, Anemia, Anemia - blood, Anemia - drug therapy, Anemia - etiology, Cardiovascular Diseases - chemically induced, Cerebral infarction, Clinical trials, Collaboration, Confidence intervals, Congestive heart failure, Darbepoetin alfa - adverse effects, Darbepoetin alfa - therapeutic use, Design, Dialysis, Drug dosages, Erythropoiesis, Erythropoietin, Female, Glycine - adverse effects, Glycine - analogs & derivatives, Glycine - therapeutic use, Heart attacks, Heart failure, Hematinics - adverse effects, Hematinics - therapeutic use, Hemodialysis, Hemoglobin, Hemoglobins - analysis, Hospitalization - statistics & numerical data, Humans, Hydroxylase, Hypoxia, Hypoxia-inducible factors, Kidney diseases, Male, Middle Aged, Myocardial infarction, Patients, Picolinic Acids - adverse effects, Picolinic Acids - therapeutic use, Prolyl hydroxylase, Prolyl-Hydroxylase Inhibitors - adverse effects, Prolyl-Hydroxylase Inhibitors - therapeutic use, Renal Insufficiency, Chronic - complications, Renal Insufficiency, Chronic - mortality, Safety, Thromboembolism